Thermo Fisher Scientific Inc. $TMO Shares Sold by Seelaus Asset Management LLC

Seelaus Asset Management LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 64.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 746 shares of the medical research company’s stock after selling 1,363 shares during the period. Seelaus Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $374,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Beacon Financial Group purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $209,000. CHICAGO TRUST Co NA lifted its stake in shares of Thermo Fisher Scientific by 19.1% during the 2nd quarter. CHICAGO TRUST Co NA now owns 1,925 shares of the medical research company’s stock worth $965,000 after purchasing an additional 309 shares during the period. PFG Advisors boosted its holdings in shares of Thermo Fisher Scientific by 10.3% during the second quarter. PFG Advisors now owns 481 shares of the medical research company’s stock worth $241,000 after purchasing an additional 45 shares during the last quarter. ARS Wealth Advisors Group LLC grew its position in shares of Thermo Fisher Scientific by 4.0% in the second quarter. ARS Wealth Advisors Group LLC now owns 28,517 shares of the medical research company’s stock valued at $14,297,000 after purchasing an additional 1,095 shares during the period. Finally, Linden Thomas Advisory Services LLC increased its stake in Thermo Fisher Scientific by 0.9% in the second quarter. Linden Thomas Advisory Services LLC now owns 13,803 shares of the medical research company’s stock valued at $6,920,000 after purchasing an additional 128 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Finally, Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last quarter. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.3%

TMO opened at $588.17 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm has a 50 day moving average price of $529.37 and a 200 day moving average price of $509.58. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market cap of $217.47 billion, a PE ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.